Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$35.91−0.53 (-1.45%)
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
Nektar Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Nektar Therapeutics's R&D Expenses for the twelve months ending Dec 31, 2025 was $117.33M, down 3.0% year over year. For fiscal 2025 it was $117.33M, down 3.0% from the year before. Over ten years it grew -4.3% a year on average. The highest annual figure on record is $434.57M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.33M | -3.0% |
| FY2024 | Dec 31, 2024 | $120.91M | +5.9% |
| FY2023 | Dec 31, 2023 | $114.16M | -47.7% |
| FY2022 | Dec 31, 2022 | $218.32M | -45.5% |
| FY2021 | Dec 31, 2021 | $400.27M | -2.1% |
| FY2020 | Dec 31, 2020 | $408.68M | -6.0% |
| FY2019 | Dec 31, 2019 | $434.57M | +8.8% |
| FY2018 | Dec 31, 2018 | $399.54M | +48.8% |
| FY2017 | Dec 31, 2017 | $268.46M | +31.7% |
| FY2016 | Dec 31, 2016 | $203.80M | +11.5% |
| FY2015 | Dec 31, 2015 | $182.79M | +23.7% |
| FY2014 | Dec 31, 2014 | $147.73M | -22.2% |
| FY2013 | Dec 31, 2013 | $190.01M | +27.8% |
| FY2012 | Dec 31, 2012 | $148.68M | +17.3% |
| FY2011 | Dec 31, 2011 | $126.77M | +17.3% |
| FY2010 | Dec 31, 2010 | $108.07M | +13.6% |
| FY2009 | Dec 31, 2009 | $95.11M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $29.71M | +3.4% |
| Q3 FY2025 | Sep 30, 2025 | $27.25M | -22.2% |
| Q2 FY2025 | Jun 30, 2025 | $29.89M | +0.5% |
| Q1 FY2025 | Mar 31, 2025 | $30.48M | +11.2% |
| Q4 FY2024 | Dec 31, 2024 | $28.75M | -4.0% |
| Q3 FY2024 | Sep 30, 2024 | $35.03M | +45.5% |
| Q2 FY2024 | Jun 30, 2024 | $29.72M | +0.1% |
| Q1 FY2024 | Mar 31, 2024 | $27.41M | -10.0% |
| Q4 FY2023 | Dec 31, 2023 | $29.94M | -13.8% |
| Q3 FY2023 | Sep 30, 2023 | $24.07M | -28.3% |
| Q2 FY2023 | Jun 30, 2023 | $29.68M | -30.6% |
| Q1 FY2023 | Mar 31, 2023 | $30.47M | -71.6% |
| Q4 FY2022 | Dec 31, 2022 | $34.74M | -65.1% |
| Q3 FY2022 | Sep 30, 2022 | $33.59M | -67.6% |
| Q2 FY2022 | Jun 30, 2022 | $42.74M | -57.8% |
| Q1 FY2022 | Mar 31, 2022 | $107.25M | +12.2% |
| Q4 FY2021 | Dec 31, 2021 | $99.61M | -3.0% |
| Q3 FY2021 | Sep 30, 2021 | $103.74M | +3.2% |
| Q2 FY2021 | Jun 30, 2021 | $101.31M | +5.1% |
| Q1 FY2021 | Mar 31, 2021 | $95.60M | -12.3% |
| Q4 FY2020 | Dec 31, 2020 | $102.72M | -6.9% |
| Q3 FY2020 | Sep 30, 2020 | $100.53M | +1.5% |
| Q2 FY2020 | Jun 30, 2020 | $96.44M | -9.6% |
| Q1 FY2020 | Mar 31, 2020 | $108.99M | -8.0% |
| Q4 FY2019 | Dec 31, 2019 | $110.37M | +1.4% |
| Q3 FY2019 | Sep 30, 2019 | $99.05M | -3.7% |
| Q2 FY2019 | Jun 30, 2019 | $106.69M | +20.8% |
| Q1 FY2019 | Mar 31, 2019 | $118.46M | +19.1% |
| Q4 FY2018 | Dec 31, 2018 | $108.88M | +33.7% |
| Q3 FY2018 | Sep 30, 2018 | $102.90M | +56.6% |
| Q2 FY2018 | Jun 30, 2018 | $88.33M | +46.6% |
| Q1 FY2018 | Mar 31, 2018 | $99.42M | +62.8% |
| Q4 FY2017 | Dec 31, 2017 | $81.43M | +62.1% |
| Q3 FY2017 | Sep 30, 2017 | $65.71M | +26.5% |
| Q2 FY2017 | Jun 30, 2017 | $60.26M | +15.1% |
| Q1 FY2017 | Mar 31, 2017 | $61.06M | – |
| Q4 FY2016 | Dec 31, 2016 | $50.23M | – |
| Q3 FY2016 | Sep 30, 2016 | $51.95M | – |
| Q2 FY2016 | Jun 30, 2016 | $52.35M | – |
See a number that looks wrong?